NEW YORK (GenomeWeb) – The Alliance Global Group and Myriad Genetics GmbH have reached a deal to promote the EndoPredict prognostic test for breast cancer. Myriad Genetics GmbH, the international subsidiary of Myriad Genetics, and Sividon Diagnostics entered into an agreement in January to co-market Sividon's EndoPredict test outside the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.